The present disclosure provides methods for treating and preventing foot pain, muscle soreness, inflammation or an inflammatory-related disorder, and itch with the administration of compositions comprising pine resin. Also provided are methods of repelling an insect by applying to a subject composition comprising pine resin.

A pharmaceutical composition for the treatment of eczema is disclosed. Also disclosed are methods of treating eczema in a subject by administering a pharmaceutical composition.

A pharmaceutical composition for the treatment of eczema is disclosed. Also disclosed are methods of treating eczema in a subject by administering a pharmaceutical composition.

Described herein are compounds of Formula I: ##STR00001##
wherein R.sub.1-R.sub.6 are as described herein, for use in the treatment of a coronavirus infection; a method of inhibiting a coronavirus 3CL protease, by contacting the 3CL protease with a compound of Formula I; as well as methods pharmaceutical composition comprising a compound of Formula I and at least one phospholipid, wherein a weight ratio of the phospholipid(s) to the compound in the composition is in a range of from 10:1 to 1:10. Further described herein is a method of treating a coronavirus infection in a subject in need thereof, by administering to the subject at least one compound that exhibits at least two of: inhibition of an activity of a 3CL protease of the coronavirus; inhibition of inflammation in the subject; and inhibition of autophagy in the subject.

Described herein are compounds of Formula I: ##STR00001##
wherein R.sub.1-R.sub.6 are as described herein, for use in the treatment of a coronavirus infection; a method of inhibiting a coronavirus 3CL protease, by contacting the 3CL protease with a compound of Formula I; as well as methods pharmaceutical composition comprising a compound of Formula I and at least one phospholipid, wherein a weight ratio of the phospholipid(s) to the compound in the composition is in a range of from 10:1 to 1:10. Further described herein is a method of treating a coronavirus infection in a subject in need thereof, by administering to the subject at least one compound that exhibits at least two of: inhibition of an activity of a 3CL protease of the coronavirus; inhibition of inflammation in the subject; and inhibition of autophagy in the subject.

The present disclosure is directed to a composition and method of enhancing skin health and appearance, as well as treating compromised skin, by applying onto the skin a composition containing a moisturizing/hydrating-effective amount of a mixture of at least: (a) an oil infusion of Calendula officinalis extract; (b) an oil infusion of Helichrysum italicum extract; (c) an oil infusion of Symphytum officinale extract; (d) an aqueous infusion of Viola tricolor extract; and (e) an aqueous infusion of at least one Mallow extract chosen from Malva sylvestris extract and Althea officinalis extract; and an emulsifying-effective amount of a dermatologically-acceptable emulsifier, wherein the composition is natural and free of a skin sensitizing-effective amount of an essential oil.

The present disclosure is directed to a composition and method of enhancing skin health and appearance, as well as treating compromised skin, by applying onto the skin a composition containing a moisturizing/hydrating-effective amount of a mixture of at least: (a) an oil infusion of Calendula officinalis extract; (b) an oil infusion of Helichrysum italicum extract; (c) an oil infusion of Symphytum officinale extract; (d) an aqueous infusion of Viola tricolor extract; and (e) an aqueous infusion of at least one Mallow extract chosen from Malva sylvestris extract and Althea officinalis extract; and an emulsifying-effective amount of a dermatologically-acceptable emulsifier, wherein the composition is natural and free of a skin sensitizing-effective amount of an essential oil.

The present disclosure describes pharmaceutical compositions and methods for reducing duration, intensity, and/or bothersomeness of common colds in humans and for reducing severity or duration of common cold symptoms such as nasal congestion, runny nose, watery eyes, dry/scratchy throat and sneezing in humans exhibiting such symptoms. The compositions herein comprise extracts of at least one of Luffa Operculata (L. operculata), S. officinale (V. sabadilla), and Galphimia Glauca (G. glauca) in a pharmaceutically acceptable carrier, and in various embodiments, comprise a mixture of all three Luffa Operculata (L. operculata) 10% extract MT, S. officinale (V. sabadilla) 3 extract, and Galphimia Glauca (G. glauca) 10% extract MT in a pharmaceutically acceptable carrier.

The present disclosure describes pharmaceutical compositions and methods for reducing duration, intensity, and/or bothersomeness of common colds in humans and for reducing severity or duration of common cold symptoms such as nasal congestion, runny nose, watery eyes, dry/scratchy throat and sneezing in humans exhibiting such symptoms. The compositions herein comprise extracts of at least one of Luffa Operculata (L. operculata), S. officinale (V. sabadilla), and Galphimia Glauca (G. glauca) in a pharmaceutically acceptable carrier, and in various embodiments, comprise a mixture of all three Luffa Operculata (L. operculata) 10% extract MT, S. officinale (V. sabadilla) 3 extract, and Galphimia Glauca (G. glauca) 10% extract MT in a pharmaceutically acceptable carrier.

A system and method of electrotherapy for enhanced drug delivery, comprising an electrode patch and an electrotherapy apparatus providing electrical current onto the electrode patch. The electrode patch contains one or more active drug ingredients in a layer of conductive gel, and the electrotherapy apparatus provides electrical current onto the electrode patch for the enhanced drug delivery of active drug ingredients. The conductive gel is in contact with a human or animal body, and the electrode patch also includes a layer of conductive sheet, a supporting layer, and conductive connectors. The conductive gel has the viscosity allowing it to adhere to skin on a human or animal body. The active drug ingredients that can be delivered through the conductive gel include: lidocaine, capsaicin, menthol, camphor, methyl salicylate, trolamine salicylate, Arnica montana, Calendula officinalis, Hypericum perforatum, Symphytum officinale, cannabidiol (CBD) or any combination of these substances. The mass fraction of the active drug ingredients can vary from 0.001% to 30%. The electrotherapy device can be reused.